# What can we learn from innovative ways of monitoring health research?





# The Global Health Network.org



supporting research through sharing methods and knowledge OXFORD

East African Clinical Consortium for Clinical Research (EACCR) E. Ayuo, KEMRI/CDC, Kisumu, Kenya Dr. K. Jeremiah, NIMR Mwanza, Tanzania Prof. P. Kaleebu, UVRI/MRC, Entebbe, Uganda E. Kivaya, KEMRI-Wellcome, Kilifi, Kenya Dr. K. Laserson, KEMRI/CDC, Kisumu, Kenya Dr. G. Miiro, UVRI, Entebbe, Uganda Dr. A. Nanvubya, UVRI/IAVI, Entebbe, Uganda Dr. P. Njuguna, KEMRI-Wellcome, Kilifi, Kenya

#### Mahidol Oxford Tropical Research Unit, Thailand (MORU)

Dr. PY Cheah, MORU, Bangkok V. Hantrakun , MORU, Bangkok

#### **University of Oxford**

Dr. T. Lang, Dept. of Tropical Medicine, Global Health Trials
T. Chantler , Dept. of Tropical Medicine, Global Health Trials/WWARN\*
Dr. P. Guerin, Dept. of Tropical Medicine, WWARN
Professor M. Parker, Dept. of Public Health, The Ethox Centre
\*WWARN is funding this research

# Background

- Need for pragmatic, trial & context specific application of regulations<sup>1</sup>
- GCP hampered by bureaucracy and misapplication<sup>2,3,4</sup>
- Regulatory monitoring model presents GCP as complex & requiring huge resources
- Tick box mentality diverts attention away from key questions about ethical process, participant safety, study endpoints and data validity

#### **Monitoring Systems**

#### **Trial Sponsors**

- Academic Institutes
- Health Organisations
- Pharmaceutical Companies
- Funding bodies
- Product Development Partnerships

Trial Sponsors' Internal Monitoring Groups

> Trial at Research Site

Contract Research Organisations

## **Research Question**

What is the value of innovative quality management schemes (situated within international research networks) which are seeking to apply a shared learning style approach to trial monitoring, and how can this value be measured?

# **Study Objectives**

- 1. Describe EACCR & MORU monitoring schemes;
- 2. Explore/analyse the perspectives & experiences of those who developed and those who are coordinating schemes;
- 3. Explore /analyse the perspectives and experiences gained by trial investigators trial team being monitored;
- 4. Explore/analyse study participants' views about the nature, purpose and practice of trial monitoring
- 5. Develop ways of evaluating & measuring the quality, performance, costs, benefits and added value of the innovating schemes.

# **Participatory Action Research<sup>8</sup>**

Planning Agree objectives



Looking Interviews, observation, document review



Implement Act on findings, design & evaluate tools Analysis Stage Transcription, Thematic Coding, Interpretation








### **EACCR Scheme**

- EACCR is an EDCPT funded network of excellence with the aim of increasing research capacity in the East African region
- Since 2010 EACCR has been piloting a reciprocal monitoring scheme to establish a pool of monitors who can undertake cross-site monitoring

#### **Key Characteristics**

- Two coordinators based in Kenya and Uganda provide oversight and logistical support
- Partner institutes nominate research staff for monitors training (currently 22 active)
- Experienced monitors are paired with less experienced monitors for mentoring
- Scheme coordinators consult with investigators to identify trials for monitoring
- Monitoring pairs are allocated trials taking place at partner institutes
- After an introduction visit the pairs develop a monitoring plan, conduct a series of site visits and compile reports for the investigators and scheme coordinators



EACCR Partner Institutes involved in the RMS










### **MORU Scheme**

- MORU is a collaboration between Mahidol University and the University of Oxford and its main offices are located in Bangkok
- MORU has study sites in Thailand and other parts of developing world across Asia and Africa
- MORU established a Clinical Trials Support Group (CTSG) in 2008

#### **Key Characteristics**


- CTSG is embedded within MORU which promotes communication and transparency
- CTSG includes experienced clinical trial coordinators, data managers and statisticians
- Members of CTSG provide assistance in planning, managing and monitoring research ٠ activities to ensure compliance with ethical and regulatory requirements
- CTSG monitors focus on findings which will impact key trial outcomes and actively involve sites in problem solving

# CTSG TRAC monitoring: Spatial Logistics



**CTSG Monitors based at the Mahidol Research Unit in Bangkok** 

## **Core Findings**



The 'What' of trial monitoring?

- Monitoring as a burden, policing -lack of credit given to investigator

   ...initially scared...it took me a while to understand that they were working for the good of the trial'
- Monitoring & regulation as a good discipline
- Critical elements:

The support role of monitoring & the scientific nature of monitoring 'Monitoring as a concept or thing that will help you do your work better (an assurance for investigators)'

• Success measures:

Trial improvements and increased site capacity

The 'How' of trial monitoring

#### • The 'Who' of monitoring

- Ethos, nature, mandate, positioning of monitoring bodies (internal, external, network)
- Accountability and organisational relationships 'identifying with sponsor and site' 'we are doing this together or...you are hiding something'
- Credentials and origins of monitors Understanding of context, willingness to learn
- What constitutes professional practice
  - Monitoring and protocol development
  - The right balance 'paperwork and observation'
  - The work approach/monitoring style
  - Relationships and interactions

# Conclusions

The MORU & EACCR schemes represent viable alternatives for monitoring health research and their value needs to be recognised and developed.

- ✓ They focus on research conduct and prioritise key outcomes and participants' safety
- They demonstrate the value of co-operative interactions between researchers & monitors
- ✓ They utilize existing scientific and monitoring expertise to build capacity and increase the quality of research

# References

- 1. WHITE, N. J. 2006. Editorial: Clinical trials in tropical diseases: a politically incorrect view. *Tropical Medicine & International Health, 11, 1483-1484.*
- 2. LANG, T., CHEAH, P. Y. & WHITE, N. J. Clinical research: time for sensible global guidelines. *The Lancet, 377, 1553-1555.*
- GRIMES, D. A., HUBACHER, D., NANDA, K., SCHULZ, K. F., MOHER, D. & ALTMAN, D. G. 2005. The Good Clinical Practice guideline: a bronze standard for clinical research. *The Lancet*, *366*, *172-174*.
- EISENSTEIN, E. L., COLLINS, R., CRACKNELL, B. S., PODESTA, O., REID, E. D., SANDERCOCK, P., SHAKHOV, Y., TERRIN, M. L., SELLERS, M. A., CALIFF, R. M., GRANGER, C. B. & DIAZ, R. 2008. Sensible approaches for reducing clinical trial costs. *Clinical Trials*, *5*, *75-84*.

# References

- 5. CLINICAL TRIALS TRANSFORMATION INITIATIVE. 2010. Developing Effective Quality Systems in Clinical Trials: An Enlightened Approach (Summary of an expert meeting). [Accessed https://www.trialstransformation.org/projects/effective-andefficient-monitoring/Workstream3 4th October 2011].
- LANE, J. A., WADE, J., DOWN, L., BONNINGTON, S., HOLDING, P. N., LENNON, T., JONES, A. J., SALTER, C. E., NEAL, D. E., HAMDY, F. C. & DONOVAN, J. L. 2011. A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance. *Journal of Clinical Epidemiology, 64, 628-636.*
- 7. CHILENGI, R., OGETII, G. & LANG, T. A. 2010. A Sensible Approach To Monitoring Trials: Finding Effective Solutions In-house. *Webmed Central Clinical Trials 1, WMC00891.*
- 8. STRINGER, E. T. 1996. Action Research: A Handbook for Practitioners, Thousand Oaks, California, SAGE.

# Thank you!

If you have any queries, please email them to <u>tamzin@globalhealthtrials.org</u>, and I will put you in contact with the research lead.